These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 36327902)
21. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079 [TBL] [Abstract][Full Text] [Related]
22. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159 [TBL] [Abstract][Full Text] [Related]
23. Detection of the Prostate Cancer Biomarker PCA3 with Electrochemical and Impedance-Based Biosensors. Soares JC; Soares AC; Rodrigues VC; Melendez ME; Santos AC; Faria EF; Reis RM; Carvalho AL; Oliveira ON ACS Appl Mater Interfaces; 2019 Dec; 11(50):46645-46650. PubMed ID: 31765118 [TBL] [Abstract][Full Text] [Related]
24. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767 [TBL] [Abstract][Full Text] [Related]
25. PCA3: from basic molecular science to the clinical lab. Day JR; Jost M; Reynolds MA; Groskopf J; Rittenhouse H Cancer Lett; 2011 Feb; 301(1):1-6. PubMed ID: 21093148 [TBL] [Abstract][Full Text] [Related]
27. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program. Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211 [TBL] [Abstract][Full Text] [Related]
28. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154 [TBL] [Abstract][Full Text] [Related]
29. Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence‑specific RNA capture. Zheng K; Dou Y; He L; Li H; Zhang Z; Chen Y; Ye A; Liu W; Kong L Oncol Rep; 2015 Nov; 34(5):2439-44. PubMed ID: 26351770 [TBL] [Abstract][Full Text] [Related]
30. The use of PCA3 in the diagnosis of prostate cancer. Hessels D; Schalken JA Nat Rev Urol; 2009 May; 6(5):255-61. PubMed ID: 19424173 [TBL] [Abstract][Full Text] [Related]
31. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer. Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000 [TBL] [Abstract][Full Text] [Related]
32. Urine PCA3 mRNA level in diagnostic of prostate cancer. Li M; Zhou D; Zhang W; Gao S; Zhou X J Cancer Res Ther; 2018; 14(4):864-866. PubMed ID: 29970667 [TBL] [Abstract][Full Text] [Related]
33. Pathological patterns of prostate biopsy in men with fluctuations of prostate cancer gene 3 score: a preliminary report. De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Porpiglia F Anticancer Res; 2015 Apr; 35(4):2417-22. PubMed ID: 25862908 [TBL] [Abstract][Full Text] [Related]
34. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709 [TBL] [Abstract][Full Text] [Related]
35. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Hessels D; Klein Gunnewiek JM; van Oort I; Karthaus HF; van Leenders GJ; van Balken B; Kiemeney LA; Witjes JA; Schalken JA Eur Urol; 2003 Jul; 44(1):8-15; discussion 15-6. PubMed ID: 12814669 [TBL] [Abstract][Full Text] [Related]
37. [Perspectives of improvement of the diagnosis of prostate cancer based on analysis of PCA3 gene expression]. Toropovsky AN; Nikitin AG; Pavlova ON; Viktorov DA Urologiia; 2019 Jun; (2):82-86. PubMed ID: 31162907 [TBL] [Abstract][Full Text] [Related]
38. Long noncoding RNA PCA3 gene promoter region is related to the risk of prostate cancer on Chinese males. Zhou W; Tao Z; Wang Z; Hu W; Shen M; Zhou L; Wen Z; Yu Z; Wu X; Huang K; Hu Y; Lin X Exp Mol Pathol; 2014 Dec; 97(3):550-3. PubMed ID: 25445501 [TBL] [Abstract][Full Text] [Related]
39. Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer. Chunhua L; Zhao H; Zhao H; Lu Y; Wu J; Gao Z; Li G; Zhang Y; Wang K Transl Oncol; 2018 Jun; 11(3):628-632. PubMed ID: 29574327 [TBL] [Abstract][Full Text] [Related]
40. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]